Thelansis

 Gastrointestinal Stromal Tumors (GISTs) are the most ordinary mesenchymal neoplasms of the gastrointestinal tract. Approximately 80% of GISTs harbor activating mutations in the KIT or PDGFRA genes that are responsible for the up-regulation of crucial signaling pathways, including MAPK and PI3K-AKT. GISTs lacking KIT and PDGFRA mutations are referred to as “wild-type” (wt)-GIST. GISTs can develop in the colon, rectum, esophagus, mesentery, and omentum and are most commonly found in the stomach (60 percent) and small intestine (25 percent). They can also evolve in the colon, rectum, esophagus, mesentery, and omentum (15 percent together). Fatigue, abdominal pain, dysphagia, satiety, and obstruction are all symptoms associated with GISTs. One or more GISTs develop in 7% of patients with neurofibromatosis type I (NF1). Most cancers start in the small intestine and do not spread quickly. Most of these GISTs are KIT and PDGFRA wild-type, but as expected, they have somatic mutations or l...